Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Biochemical Reagents >  Agonist Inhibitors >  ADH 1

ADH 1

Basic information Safety Supplier Related

ADH 1 Basic information

Product Name:
ADH 1
Synonyms:
  • ADH 1
  • Exherin
  • Exherin TFA
  • Exherin (ADH-1)
  • ADH-1 Exherin
  • CS-2142
  • L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidyl-L-alanyl-L-valyl-, cyclic (1→5)-disulfide
  • (4R,7S,10S,13S,16R)-13-((1H-Imidazol-5-yl)methyl)-16-acetamido-7-isopropyl-10-methyl-6,9,12,15-tetraoxo-1,2-dithia-5,8,11,14-tetraazacycloheptadecane-4-carboxamide
CAS:
229971-81-7
MF:
C22H34N8O6S2
MW:
570.69
Product Categories:
  • Inhibitors
  • API
Mol File:
229971-81-7.mol
More
Less

ADH 1 Chemical Properties

Boiling point:
1183.4±65.0 °C(Predicted)
Density 
1.40±0.1 g/cm3(Predicted)
storage temp. 
Keep in dark place,Sealed in dry,Store in freezer, under -20°C
solubility 
DMSO:2.2(Max Conc. mg/mL);3.86(Max Conc. mM)
form 
A solid
pka
13.13±0.70(Predicted)
color 
White to off-white
InChIKey
FQVLRGLGWNWPSS-BXBUPLCLSA-N
SMILES
S1SC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C1)C(=O)N)C(C)C)C)Cc2[nH]cnc2)NC(=O)C
More
Less

Safety Information

WGK Germany 
WGK 3
Storage Class
11 - Combustible Solids
More
Less

ADH 1 Usage And Synthesis

Uses

ADH-1, an N-cadherin antagonist, inhibits N-cadherin mediated cell adhesion.

Biological Activity

ADH-1 is an N-cadherin (CD325; NCAD) antagonist th at selectively inhibits NCAD-dependent neurite outgrowth (IC50 = 323 μM; PN1-2 r at cerebral neurons on monolayer of chick NCAD-expressing 3T3), while exhibiting no effect against integrin receptor-dependent neurite outgrowth. ADH-1 inhibits NCAD-mediated signaling events in cultures (0.2-2.5 mg/mL) and exhibits anti-tumor efficacy in vivo (50-100 mg/kg i.p. in rats and mice).

in vivo

ADH-1 (50 mg/kg) significantly prevents tumor growth and metastasis in a mouse model for pancreatic cancer. ADH-1 prevents tumor cell invasion and metastasis in an orthotopic model for pancreatic cancer using N-cadherin overexpressing BxPC-3 cells[1].
ADH-1, at the dosages evaluated, does not display either antiangiogenic activity in a rat aortic ring assay or antitumor potential in a PC3 subcutaneous xenograft tumor model[2].
In A375, but not DM443 xenografts, ADH-1 treatment increases phosphorylation of AKT at serine 473. ADH-1 slightly diminishes N-cadherin expression in both xenografts[3].

References

[1] Shintani Y, et al. ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression. Int J Cancer. 2008 Jan 1;122(1):71-7. DOI:10.1002/ijc.23027
[2] Li H, et al. ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer. Anticancer Drugs. 2007 Jun;18(5):563-8. DOI:10.1097/CAD.0b013e328020043e
[3] Turley RS, et al. Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma. Ann Surg. 2015 Feb;261(2):368-77 DOI:10.1097/SLA.0000000000000635

ADH 1Supplier

Alabiochem Tech.Co., Ltd.
Tel
512-58900862 400-0707518
Email
sales@alabiochem.com
MedChemexpress LLC
Tel
021-58955995
Email
sales@medchemexpress.cn
AdooQ BioScience, LLC
Tel
+1 (866) 930-6790
Email
info@adooq.com
Wuxi Zhongkun Biochemical Technology Co., Ltd.
Tel
0510-85629785 18013409632
Email
sales@reading-chemicals.com
AdooQ Bioscience CHINA
Tel
025-58849295 18951903616;
Email
info@adooq.cn